RecruitingNCT05577689
Novel Therapy Target in Metastatic Prostate Cancer
Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer
Sponsor
Fudan University
Enrollment
100 participants
Start Date
Aug 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria4
- Histologically confirmed prostate cancer
- metastatic disease confirmed by image examination
- Patients who can undergo surgery or biopsy for prostate cancer
- Able to provide informed consent
Exclusion Criteria4
- Patients diagnosed with other types of cancer besides prostate cancer
- Not accessible to surgery sample
- Patients fail to provide informed consent
- Other situation that researchers think are unsuitable for this study
Interventions
OTHERTissue
Tissue will be derived from patients during a standard of care procedure
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05577689